Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06393816 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Study acronym: FIRST-NEC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 22 to 31
    • Start date changed from estimate of May 2024 to Jun 13, 2024
    v3
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Centre Leon Berard
70 trials monitored
See 2 trials at risk
Lung Cancer
4,790 trials monitored
See 263 trials at risk
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced LCNEC confirmed by centralized expert-pathologist review
Trial Details
NCT Number NCT06393816
Lead Sponsor Centre Leon Berard
Collaborators: Groupe Francais De Pneumo-Cancerologie
Conditions
(from sponsor)		 Large Cell Neuroendocrine Carcinoma of the Lung
Related terms Lung Neoplasms
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov